Final figures for 2016 confirm good year-end results, says Stada Arz

3 April 2017

German generic drugmaker Stada Arzneimittel (SAZ: Xetra), currently evaluating various takeover approaches, has reported that group sales for 2016 increased by 1% to 2.14 billion euros ($2.29 billion). Adjusted to currency and portfolio effect, sales increased 3% to 2.17 billion euros.

The earnings situation in the reporting year was shaped by special items – by expenses in connection with reorganization decisions in particular – and totaled 116.7 million euros before and 91.4 million euros after taxes, said Stada.

Reported operating profit leapt 20% to 178.1 million euros. Adjusted operating profit increased 4% to 294.4 million euros. Reported earnings before interest, taxes, depreciation and amortization (EBITDA) showed an increase of 2% to 398.0 million euros. Reported earnings per share fell to 1.38 euros from 1.79 euros the previous year, though adjusted EPS increased to 2.85 euros, up from 2.69 euros.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK